TFF Pharmaceuticals Announces Second Patient Successfully Treated with Voriconazole Inhalation Powder Through Compassionate Use Program

Marks the Second Patient to Clinically Benefit from Administration of Voriconazole Inhalation Powder Using Thin Film Freezing-Based Technology Positive Results from First Patient Treated with TFF... | November 1, 2022

Related Keywords

Australia ,Melbourne ,Victoria ,Texas ,United States ,Dale Christensen ,Gregory Snell ,Corey Davis ,Bradley Gardiner ,Raena Mina ,Administration Of Voriconazole Inhalation Powder ,International Congress On Lung Transplantation ,Nasdaq ,Head Of Clinical Development ,Lifesci Communications ,Head Of Lung Transplant Service ,Pharmaceuticals Inc ,Globenewswire Inc ,Second Patient ,Clinically Benefit ,Voriconazole Inhalation Powder ,Using Thin Film Freezing Based ,First Patient Treated ,Thin Film Freezing ,Invasive Pulmonary Aspergillosis ,Forced Expiratory Volume ,Forced Vital Capacity ,Medical Head ,Lung Transplant Service ,Clinical Development ,Film Freezing ,Tacrolimus Inhalation Powder ,Relations Contact ,Tff Pharmaceuticals ,Nc Stock Exchange ,News ,Information ,Press Release ,Parks ,The ,Second ,Patient ,O ,Linically ,Benefit ,Rom ,Administration ,F ,Oriconazole ,Inhalation ,Powder ,Sing ,Chin ,Film ,Technology ,Positive ,Results ,First ,Reated ,Ith Tffp Us87241j1043 ,